Novogen finds new anticancer candidates
07 May, 2013 by Dylan Bushell-EmblingNovogen’s (ASX:NRT) anticancer program has identified two second-generation drug candidates, showing promise in pancreatic cancer and melanoma, and one will be fast-tracked to the clinic.
CardioCel studies presented at medical conferences
06 May, 2013 by Dylan Bushell-EmblingData from studies involving Allied Healthcare’s (ASX:AHZ) CardioCel technology in cardiovascular repair and stem cell growth were presented at two recent medical meetings.
Govt taking applications for precincts initiative
03 May, 2013 by Dylan Bushell-EmblingThe Australian life science industry has a chance to apply to be one of up to 10 Industry Innovation Precincts - consortia of businesses and universities aimed at fostering R&D and competitiveness.
Public companies must monitor social media
03 May, 2013 by Dylan Bushell-EmblingNew ASX disclosure guidelines on monitoring social media for leaks of market-sensitive information herald a new era of reporting compliance, according to Buchan Consulting.
Biotron releases more data from HCV trial
02 May, 2013 by Dylan Bushell-EmblingBiotron has presented some pharmacokinetic data from its phase IIa trial of BIT225 in HCV, showing no evidence of drug resistance growth.
pSivida partner gets new PDUFA date for Iluvien
02 May, 2013 by Dylan Bushell-EmblingThe US FDA will decide by 17 October whether to approve pSivida (ASX:PVA) licensee Alimera’s NDA for Iluvien in diabetic macular edema.
Concern over plan to remove or limit patent extensions
02 May, 2013AusBiotech has made a submission in response to the Pharmaceutical Patent Review’s (PPR) Draft Report, stating its disappointment at the options provided under recommendation 5 to remove or reduce Australia’s patent extension provisions.
Alchemia wins US patent for drug discovery platform
01 May, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has secured US patent protection for its VAST small molecule drug discovery platform through to 2025.
Imugene wins Chinese Linguet patent
01 May, 2013 by Dylan Bushell-EmblingImugene (ASX:IMU) has secured its second patent from an Asian market protecting the use of its Linguet drug-delivery technology for formulations of drugs to prevent bone loss.
Australian biotech sector grew 7% in 2012
01 May, 2013 by Dylan Bushell-EmblingRevenue from the world’s major biotech markets grew 8% in 2012, but weak R&D spending growth is a sign that the sector has still not fully recovered from the GFC, says Ernst & Young.
pSivida partner launches Iluvien in the UK
01 May, 2013 by Dylan Bushell-EmblingAlimera has launched Iluvien, the intravitreal implant designed by pSivida (ASX:PVA), into the UK market.
ResMed posts record profit for March quarter
30 April, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) grew its March-quarter profit by 31% and revenue by 10%, thanks to strong gains in the Americas region.
Public consultations on Asian Century country strategies
30 April, 2013Australia’s position in the Asia-Pacific region, in what has been dubbed the Asian Century, means biotechnology is poised in the right industry in the right region.
Elastic patch supports cardiac cell growth
30 April, 2013Scientists are a step closer to being able to repair damaged human heart tissue thanks to a world-leading research collaboration between the University of Sydney and Harvard University.
STA cleared to market C. difficile treatment
26 April, 2013 by Dylan Bushell-EmblingSpecialised Therapeutics Australia has won approval to market fidaxomicin - the C. difficile treatment licensed from Optimer Pharmaceuticals - in Australia.
